120
Participants
Start Date
March 13, 2025
Primary Completion Date
August 31, 2026
Study Completion Date
July 31, 2027
RC148 plus Carboplatin and Paclitaxel/pemetrexed
RC148; Carboplatin; Paclitaxel; pemetrexed
RC148
RC148 Monotherapy
RECRUITING
Beijing Tiantan Hospital of Capital Medical University, Beijing
RECRUITING
Peking University Cancer Hospital, Beijing
RECRUITING
Shunde Hospital of Southern Medical University, Foshan
RECRUITING
The First People's Hospital of Shunde, Foshan
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
The First affiliated Hospital of Guangzhou Medical University, Guangzhou
RECRUITING
Jiangmen Central Hospital, Jiangmen
RECRUITING
The Second Affiliated Hospital of Guilin Medical College, Gulin
RECRUITING
Affiliated Cancer Hospital of Guangxi Medical University, Nanning
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Nanyang Second General Hospital, Hanyang
RECRUITING
The First Affiliated Hospital of Xinxiang Medical College, Xinxiang
RECRUITING
Henan cancer hospital, Zhengzhou
RECRUITING
Union Hospital Tongji Medical College Huazhong University Of Science And Technologe, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
Binzhou Medical University Hospital, Binzhou
RECRUITING
Jinan Central Hospital, Jinan
RECRUITING
Linyi Cancer Hospital, Linyi
RECRUITING
Tianjin Medical University Cancer Institute Hospital, Tianjin
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Taizhou Hospital of Zhejiang Province, Taizhou
RemeGen Co., Ltd.
INDUSTRY